Oseltamivir (phosphate)
Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.
Product Specifications
CAS Number
[204255-11-8]
Product Name Alternative
GS 4104 (phosphate)
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Influenza Virus
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/Oseltamivir-phosphate.html
Purity
99.93
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)
Smiles
O=C(OCC)C1=C[C@H]([C@@H]([C@H](C1)N)NC(C)=O)OC(CC)CC.OP(O)(O)=O
Molecular Formula
C16H31N2O8P
Molecular Weight
410.40
Precautions
H302, H315, H319, H335
References & Citations
[1]Huang H, et al. Transplacental transfer of Oseltamivir phosphate and its metabolite Oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population. J Matern Fetal Neonatal Med. 2016 Aug 8:1-5.|[2]de Oliveira JT, et al. Anti-influenza neuraminidase inhibitor Oseltamivir phosphate induces canine mammary cancer cell aggressiveness. PLoS One. 2015 Apr 7;10 (4) :e0121590.|[3]Li P, et al. A Simple and Robust Approach for Evaluation of Antivirals Using a Recombinant Influenza Virus Expressing Gaussia Luciferase. Viruses. 2018 Jun 13;10 (6) . pii: E325.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Acta Pharm Sin B. 2025 May 29.|Antiviral Res. 2025 May 3:106174.|Antiviral Res. 2020 Apr;176:104751. |Arch Pharm Res. 2018 Jun;41 (6) :664-676.|Bioeng Transl Med. 2020 Dec 1;6 (1) :e10196.|Biomed Pharmacother. 2018 Jan:97:385-394.|bioRxiv. 2023 Aug 12.|bioRxiv. 2024 May 8:2024.05.06.592815.|bioRxiv. 2025 Jul 31.|Biosci Biotechnol Biochem. 2020 Apr;84 (4) :774-779.|BMC Microbiol. 2025 May 15;25 (1) :292.|Cell Prolif. 2021 Jan;54 (1) :e12953.|Chemosphere. 2015 Jul:131:41-7.|Front Cell Dev Biol. 2021 Dec 17:9:802502.|Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.|Inflammation. 2024 Feb;47 (1) :30-44.|Int J Mol Sci. 2019 Dec 12;20 (24) :6261.|Int J Mol Sci. 2022 Apr 1;23 (7) :3940.|J Ethnopharmacol. 2024 Jan 30;319 (Pt 2) :117290.|J Med Virol. 2023 Jul;95 (7) :e28968.|Lab Invest. 2020 Dec;100 (12) :1602-1617.|Sci Rep. 2021 Aug 11;11 (1) :16293.|Signal Transduct Target Ther. 2021 Apr 24;6 (1) :165.|Virol J. 2025 Jun 4;22 (1) :181.|Virology. 2020 Jun;545:1-9.|Virology. 2025 Oct:611:110642.|Viruses. 2018 Jun 13;10 (6) . pii: E325. |ACS Infect Dis. 2025 Jun 13;11 (6) :1437-1447.|Animal Model Exp Med. 2025 Jan 26.|Antiviral Res. 2016 Mar:127:68-78.|bioRxiv. 2024 Jul 7:2024.07.04.601620.|Chem Biodivers. 2024 Nov 24:e202402465.|Food Funct. 2016 Apr 20;7 (4) :2052-9. |Int J Infect Dis. 2024 Jun 27:107134.|Int J Mol Sci. 2025 Jun 3;26 (11) :5358.|NPJ Digit Med. 2025 Nov 21, 8 (1) :712.|Pharmaceuticals (Basel) . 2025 Aug 30;18 (9) :1306.|Phytochemistry. 2023 Oct:214:113829.|Phytomedicine. 2024 Jul:129:155534.|SSRN. 2024 Aug 7.|Virol Sin. 2024 Aug 19:S1995-820X (24) 00134-2.|Virology. 2024 Feb:590:109954.|Virulence. 2024 Dec;15 (1) :2301242.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
